Pharmaceutical

Enara Bio secures $32.5m for ‘Dark Antigen’ cancer therapies

Pfizer and Merck KGaA’s venture capital arms were among the backers in the Series B round.

Oct 4, 2024 - 04:00
Enara Bio secures $32.5m for ‘Dark Antigen’ cancer therapies
Pfizer and Merck KGaA’s venture capital arms were among the backers in the Series B round.
Read the original article

Tags:

Previous Article

Chronic diseases “as urgent as climate change,” says Novo Nordisk CSO

Next Article

Healthcare Payers for the Pharmaceutical Industry

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: As demand for Covid shots wanes, Moderna seeks its next success

STAT+: As demand for Covid shots wanes, Moderna seeks i...

Jun 26, 2023

FDA advisers endorse updating Covid vaccines to target latest Omicron strain

FDA advisers endorse updating Covid vaccines to target ...

Jun 16, 2023

MSD secures worldwide license for LaNova’s LM-299

MSD secures worldwide license for LaNova’s LM-299

Nov 15, 2024